Design Therapeutics, Inc.

Design Therapeutics, Inc. reported a net loss of $69.8 million for fiscal year 2025, driven by a loss from operations of $79.5 million. The company generated no revenue during the period. Operating expenses totaled $79.5 million, consisting primarily of research and development costs of $59.1 million and general and administrative expenses of $20.3 million. Interest income of $9.7 million partially offset the operating loss. The company ended the year with $226.2 million in total assets, including $223.8 million in current assets comprised of $16.9 million in cash and cash equivalents and $203.0 million in investment securities. Total liabilities were $13.7 million, resulting in stockholders' equity of $212.5 million. Net cash used in operating activities was $54.4 million, while investing activities provided $22.9 million and financing activities provided $25.7 million, leading to a net decrease in cash and cash equivalents of $5.7 million for the year.

Key Takeaways